


# EXACT SCIENCES ANNOUNCES THIRD QUARTER 2022 RESULTS

Reports Record Revenue, Raises Full-Year Guidance,  
Accelerates Path to Profitability



Exact Sciences third quarter results demonstrate the **strength of our business and the unique platform this team has built to engage patients and physicians**. As we quickly approach profitability and make more innovative cancer tests available to patients, our Cologuard® and Oncotype DX® tests, best-in-class customer experience, broad sales and marketing reach, and powerful lab and technology foundation will continue to gain momentum and help achieve our vision to eradicate cancer.

— KEVIN CONROY, CHAIRMAN & CEO

## HIGHLIGHTS

DELIVERED A TOTAL OF **960K TESTS AND A RECORD NUMBER** OF COLOGUARD® AND ONCOTYPE DX® RESULTS



IMPROVED OUR ADJUSTED EBITDA LOSS BY **MORE THAN 70%** FROM LAST QUARTER AND **86%** FROM THE FIRST QUARTER



ACCELERATED OUR PATH TO **POSITIVE ADJ. EBITDA** TO THE THIRD QUARTER OF 2023 AHEAD OF PREVIOUS TARGET OF 2024



DISPLAYED **POWER OF MULTI-CANCER EARLY DETECTION** APPROACH AT ESMO



ENHANCED **COLOGUARD COLLECTION KIT** TO GIVE PATIENTS MORE TIME TO GET SAMPLES BACK TO OUR LAB



MADE OUR HEREDITARY CANCER TEST, **RISKGUARD™**, AVAILABLE TO ONCOLOGISTS THROUGH AN EARLY-ACCESS PROGRAM



## EXACT SCIENCES BY THE NUMBERS

450



R&D TEAM MEMBERS

1,300



PERSON COMMERCIAL TEAM

90



COUNTRY PRESENCE

960K



PEOPLE TESTED IN 3Q22